Zacks: Brokerages Anticipate TG Therapeutics Inc (NASDAQ:TGTX) to Announce -$0.37 EPS

Wall Street brokerages predict that TG Therapeutics Inc (NASDAQ:TGTX) will announce earnings per share (EPS) of ($0.37) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for TG Therapeutics’ earnings, with estimates ranging from ($0.43) to ($0.30). The firm is scheduled to report its next quarterly earnings results on Tuesday, February 11th.

According to Zacks, analysts expect that TG Therapeutics will report full year earnings of ($1.96) per share for the current financial year, with EPS estimates ranging from ($2.19) to ($1.83). For the next financial year, analysts forecast that the business will report earnings of ($1.45) per share, with EPS estimates ranging from ($1.98) to ($0.76). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.33). The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 123,130.93% and a negative return on equity of 2,411.79%.

A number of brokerages recently commented on TGTX. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of TG Therapeutics in a research note on Tuesday, November 12th. Zacks Investment Research cut TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. BidaskClub raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 7th. ValuEngine lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. Finally, Cantor Fitzgerald lowered their price target on shares of TG Therapeutics from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $12.95.

Shares of NASDAQ TGTX traded down $0.13 during mid-day trading on Friday, hitting $7.80. The company had a trading volume of 1,428,800 shares, compared to its average volume of 1,612,497. TG Therapeutics has a 12 month low of $3.32 and a 12 month high of $9.38. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 2.77. The firm’s 50 day simple moving average is $6.40 and its two-hundred day simple moving average is $6.92.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in TG Therapeutics by 5.0% in the 2nd quarter. SG Americas Securities LLC now owns 30,858 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 1,481 shares in the last quarter. Rhumbline Advisers boosted its position in TG Therapeutics by 2.1% during the 3rd quarter. Rhumbline Advisers now owns 95,679 shares of the biopharmaceutical company’s stock worth $537,000 after acquiring an additional 1,976 shares during the period. Aperio Group LLC bought a new position in shares of TG Therapeutics in the second quarter worth $32,000. Parametric Portfolio Associates LLC grew its stake in shares of TG Therapeutics by 45.4% in the second quarter. Parametric Portfolio Associates LLC now owns 21,152 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 6,609 shares in the last quarter. Finally, Bank of Montreal Can grew its stake in shares of TG Therapeutics by 1,119.0% in the second quarter. Bank of Montreal Can now owns 8,143 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 7,475 shares in the last quarter. 52.97% of the stock is currently owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Featured Article: Understanding the different types of bonds

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.